West German Study Group

This study tests a personalized treatment plan for people with HER2-positive early breast cancer. It compares a newer drug (trastuzumab-deruxtecan) against standard chemotherapy combinations to see which works better and causes fewer side effects. About 702 participants will rece…

This Phase 3 trial tests whether the drug elacestrant can help prevent breast cancer from coming back in people with high-risk HR+/HER2- early breast cancer. About 1,520 participants will receive either elacestrant or standard hormone therapy for up to 7.5 years. The study compar…

This phase 3 study tests whether adding capivasertib to standard hormone therapy helps people with HR+/HER2- advanced breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib plu…

This phase 3 trial is testing whether a targeted drug called sacituzumab govitecan (Trodelvy), alone or combined with the immunotherapy pembrolizumab (Keytruda), can effectively treat low-risk triple-negative breast cancer before surgery. The study aims to see if these drugs can …

This study follows premenopausal women with a common type of early breast cancer to see how well different treatments work over time. Participants either receive hormone therapy (with or without ovarian suppression) or chemotherapy followed by hormone therapy. The goal is to unde…